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Abstract
Background: Accurate diagnosis of Clostridium difficile infection (CDI) is paramount for patient management. The
wrong diagnosis places patients at risk, delays treatment, and/ or contributes to transmission of infection in the
healthcare setting. Although amplification of the toxin B gene by polymerase chain reaction (PCR) is a sensitive
method for detecting toxigenic C. difficile, false negative results still occur and could impact the diagnosis and
treatment of this infection.
Methods: This study investigated 48 patients that tested negative for toxigenic C. difficile via GeneXpert C. difficile epi
test, while simultaneously testing positive for toxigenic C. difficile via stool culture. Fifty discrepant samples were
collected over a 15-month period and all C. difficile isolates were characterized by ribotype. Patient charts were
reviewed to assess whether discrepant results impacted the treatment course or clinical outcome of affected patients.
Results: Fifty samples of a total of 2308 samples tested in an acute healthcare facility over a 15-month period had
negative PCR and positive stool culture for toxigenic C. difficile. C. difficile isolated from the discrepant samples resulted
in diverse ribotyping patterns suggesting they were derived from different strains. The samples belonged to patients
who were distributed evenly between age groups and wards in the hospital. In the majority of cases, the false negative
C. difficile test results did not seem to impact the clinical outcome in these patients.
Conclusions: The PCR limit of detection may impact the results of molecular methods for C. difficile detection. Both
clinical and analytical sensitivity of C. difficile tests should be considered when deciding which diagnostic assay to use,
and clinical correlates should be examined carefully before excluding CDI as a cause of disease.
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Background
Accurate diagnosis of Clostridium difficile infection (CDI)
is crucial for proper treatment and for preventing the
spread of the pathogen in healthcare facilities. The selection
of diagnostic tests to confirm CDI is controversial because
of the variety of laboratory methods that are available and
used across various facilities, and lack of standard recom-
mendations for testing. The controversy is compounded by
the presence of two reference methods, the cell cytotoxicity
assay (CCTA), which detects C. difficile toxin presence dir-
ectly from the stool using mammalian cell culture, and
toxigenic culture (TC), in which C. difficile is cultured first,
and the toxins in the bacterial culture supernatant are de-
tected using the CCTA [1, 2]. Diagnostic methods for the
laboratory detection of CDI can be categorized into three
groups based on the detected target: 1) culture based
methods, 2) methods based on detecting toxins produced
by the bacteria, and 3) molecular methods based on detect-
ing the toxin B gene (tcdB). Each of the three methods has
its own advantages and disadvantages. Culture methods
produce a bacterial culture that can be used for down-
stream testing (e.g. toxin gene detection, ribotyping); how-
ever, it is a time consuming method and not practical due
to the long turn-around time. Molecular methods have ad-
vantages of rapid testing with short turn-around-time and
high analytical sensitivity [3], but not necessarily clinical
sensitivity to distinguish C. difficile colonization versus
symptomatic CDI [4]. Many laboratories are currently using
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molecular methods to detect toxin B for the diagnosis of
CDI [5–8], and new technologies are easy to use even as a
point of care test (POCT) [9]. Molecular assays have also
been shown to be superior to toxin EIAs, CCTA, and 2-
step algorithms, but not to TC [10]. Immunoassay methods
based on detecting toxins A and B are recognized as less
sensitive for detecting toxigenic C. difficile (the sensitivities
of these assays varied from 31.7 % to 55.2 %) [11, 12], but
are still used by some laboratories as part of an algorithm
for detecting toxigenic C. difficile. Glutamate dehydrogen-
ase assay has been proposed as the first step in two-stage
algorithms for diagnosis of CDI, but their low specificity
makes them unsuitable as standalone tests [2].
The choice of an analytical method that is accurate, fast,
and correlates with the clinical diagnosis of CDI can be
challenging. The prevalence of asymptomatic colonization
with C. difficile is 7 %–26 % among adult inpatients in acute
care facilities [13]. This proportion of colonized carriers can
reach up to 50 % in facilities where CDI is endemic [14].
Diarrhea is a sign of CDI, but many patients who are
colonized with C. difficile may have diarrhea for reasons
other than CDI. This situation may result in unnecessary
treatment or initiation of strict isolation procedures in
hospital [4]. The reference methods for C. difficile testing
have different values and advantages, for example, TC iden-
tifies patients who are potentially infectious if they have
diarrhea (high analytical sensitivity) while CCTA is a better
test for the laboratory confirmation of CDI (having high
clinical sensitivity), although further research should be
conducted to confirm if CCTA sensitivity is improved with
additional TC [1, 15]. Analysis of outcomes in CDI patients
showed that poorer outcomes correlated with detectable
free toxin in stool than positive C. difficile culture alone [2].
Based on the aforementioned results it would seem logical
to perform highly specific rapid assays for the detection of
C. difficile toxins in stool, however rapid assays have a
sensitivity of 30–50 % [16].
In this study, we investigated a subgroup of 48 pa-
tients that tested negative by a molecular test (Cephied
GeneXpert C. difficile epi test) while testing positive for
toxigenic C. difficile by culture. These samples were
collected between June 2012 and August 2013 and were
tested retrospectively for C. difficile by culture. We also
investigated whether the molecular test missed certain
groups of C. difficile ribotypes or CDI patients and
whether false negative C. difficile results had an impact
on patients’ clinical outcomes.
Methods
Study population
All work performed in this study was approved by the
Institutional Research Ethics Board (REB) of Health Sci-
ences North (HSN) in Sudbury, Ontario, Canada. Test-
ing for C. difficile by GeneXpert was part of patient care,
and delegated review was given to allow for the research
work. This study was conducted in a 500 bed acute
healthcare facility, and comprised patients who tested
negative for C. difficile using the GeneXpert C. difficile
epi test, but had positive cultures for toxigenic C. difficle.
Patients charts were analyzed during the 15-month
period to account for all other occasions of C. difficle
testing. Patient outcomes were measured based on mor-
tality and C. difficile related morbidities.
C. difficile testing by GeneXpert and C. difficile Culture
Stool samples from patients with diarrhea, and sus-
pected of having CDI, were tested in the diagnostic la-
boratory for C. difficile using the GeneXpert C. difficile
epi test following manufacturer’s instructions [3, 17]. C.
difficile cultures were performed in the research labora-
tory. Briefly, stool samples were mixed with an equal
volume of 100 % ethyl alcohol for 60 min at room
temperature. One hundred microliters of the mixture
were spread on Clostridium difficile base agar plates
(CDBA) (Oxoid, Inc), supplemented with 0.1 % tauro-
cholate (Sigma), norfloxacin 12 mg/L, moxalactam
32 mg/L, Cystein-HCl 0.5 g/L and 7 % defibrinated
horse blood and incubated at 36 ± 0.5 °C for 72 to 96 h
under anaerobic conditions (90 N2, 5 CO2, and 5 H2).
Presumptive identification as C. difficile was based on
colony size, morphology and fluorescence properties
[18]. Isolated single C. difficile colonies were picked and
inoculated into 0.5 mL of pre-reduced Chopped Meat
Glucose Broth (CMGB) (Anaerobic Biosystems, USA)
and incubated for 72 to 96 h under anaerobic condi-
tions. Bacteria and spores were collected from the broth
medium by centrifugation at 13,000xg for 5 min, and the
DNA was extracted by boiling the sediment in 1 %
Chelex-100 resin (Sigma, Inc) suspension for 20 min.
Samples were centrifuged at 13000xg for 5 min, and the
supernatant was used for downstream testing.
Multiplex PCR for identifying toxins A and B, and
Ribotyping
Multiplex PCR was performed on presumptive C. diffi-
cile isolates to detect the Toxin A gene (tcdA), Toxin B
gene (tcdB), and the triose phosphate isomerase gene
(tpi) as described previously [19].
Ribotyping was performed using the method described
by Bidet [20]. The primers used for ribotyping were 5′-
GTG CGG CTG GAT CAC CTC CT-3′ (16S primer)
and 5′-CCC TGC ACC CTT AAT AAC TTG ACC-3′
(23S primer). Amplification reactions were performed
using Qiagen Multiplex PCR plus kit (Qiagen, CA), 50
pmoles of each primer and 100 ng of DNA. Amplifica-
tion conditions for ribotyping reaction were 1 cycle of
6 min at 94 °C for denaturation; 35 cycles of 1 min at
94 °C, 1 min at 57 °C, and 1 min at 72 °C; and a final
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extension cycle of 7 min at 72 °C. The reactions were
carried out in an Eppendorf Mastercycler® nexus.
Ribotyping amplification products were fractionated
by capillary gel electrophoresis using the 2100 Bioanaly-
zer (Agilent Technologies). Briefly, DNA 1000 chip was
prepared and used according to manufacturer’s instruc-
tions, and 1 μl of PCR product was loaded into the sam-
ple well. The chip was run using preassigned program.
Data were analyzed using Gelcompar II v6.1 software
(Applied Maths). Ribotyping patterns were compared to
an international reference collection (Cardiff/ECDC Col-
lection) and assigned the corresponding designation (e.g.
027). When ribotype patterns were not consistent with
reference strains, internal nomenclature was assigned.
Statistical analysis
Statistical analyses were performed using MedCalc for
Windows, version 12.5 (MedCalc Software, Ostend,
Belgium). Observed agreement and Kappa value were




Study population and C. difficile testing
During the study period, a total of 2308 samples were
tested for toxigenic C. difficle by GeneXpert (diagnostic
laboratory) and culture methods (research laboratory)
over a 15-month period. The observed agreement of the
results of the two tests was 95.1 % (kappa, 0.78). A total
of 295 samples tested positive by GeneXpert, while 2013
samples were negative by GeneXpert.
The sensitivity, specificity, PPV and NPV for the
GeneXpert method were 82, 97, 79 and 99 %, respect-
ively when compared to the results obtained by culturing
(Table 1). Toxigenic C. difficile was recovered by culture
from 50 samples (from 48 patients) that tested negative
by GeneXpert. There were 24 males and 24 females, and
the average age of the patients was 64 years. Samples
were collected from patients from intensive care [10],
medical (16) and surgical units (8), and 14 patients from
outpatient clinics. All C. diffficle isolates were confirmed
as toxigenic C. difficile by multiplex PCR, and consisted
of diverse group of 21 different ribotypes (Table 2).
False negative PCR results
Upon examining the GeneXpert results, 40 out of the 50
samples examined in this study were negative for all 3
components of the test (ToxB, Binary toxin and the tcdC
deletion). In 7 (14 %) of the discrepant samples, an
amplification curve for toxin B target was detected by
GeneXpert assay; however, the curve failed to reach the
positivity threshold. In addition, 4 (8) samples were posi-
tive for the Binary toxin by GeneXpert but negative for
toxin B, and another 2 (4 %) samples showed a tcdC dele-
tion. Toxin gene PCR was performed on C. difficile
isolates recovered by culture and 40 samples were A + B+,
7 samples were A-B+, and 3 samples were A-B+ but with
a variant that showed a deletion in toxA gene (Table 2).
Ribotype 020 was the most frequent type among the 50
samples, with 9 samples making up this group. Eight sam-
ples had the ribotype 046, and 5 samples had the ribotypes
027 (Table 2). This distribution followed the general distri-
bution of toxigenic C. difficile isolated from CDI patients
at HSN (unpublished data).
The distribution of cases in this study reflected the
relative sizes of the units, where almost one third of the
cases (16 cases) originated from medical wards. Fourteen
cases were outpatients, and the rest of cases were
distributed between surgery patients and intensive care
units patients.
Table 1 Comparison of performance of GeneXpert C. difficile
test and C. difficile culture followed by toxin PCR for samples
tested during the study period
Culture
+ -








Table 2 Ribotypes and toxinotypes of C. difficile isolates
recovered from 50 GeneXpert negative samples
Toxin PCR
Ribotype Number of isolates A + B+ A-B+ A(Del)B+
001 1 1
002 3 1 1 1
020 9 6 3
027 5 5
046 8 6 1 1
056 2 1 1
126 3 2 1
137 4 4
OVC F 2 2
Z 2 2
Other ribotypesa 11 11
Total 50 41 6 3
aOther ribotypes represented only once in this work include M, 017, 053, 106,
S50 and 6 other unique types
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Clinical features
When we examined the charts for the 48 patients from
this study, 16 patients were tested for C. difficile only
once over the study period, while another 16 patients
were tested more than once, but were consistently nega-
tive by GeneXpert C. difficile epi test. For these 32 pa-
tients, there was no chance of identifying them as C.
difficile positive by GeneXpert test.
On the other hand, 16 patients tested positive by
GeneXpert C. difficile epi test on other occasions. Of
these, 8 patients tested positive in other occasions (4
tested positive before and 4 after the negative test). The
other 8 patients tested both positive and negative by
GeneXpert C. difficile epi test on multiple occasions
(with 5 patients having the first test on record as posi-
tive and 3 as negative) (Table 3). For the patients that
were tested multiple times with mixed results, the pa-
tients’ records indicated clearly that these patients had
a history of CDI.
For the 16 patients that were tested only on one occa-
sion for C. difficle, there was no chance of diagnosing
these patients with CDI, but their chart review revealed
that only one patient presented with a GI related illness,
and who had a history of ulcerative colitis. Another
patient died from an unrelated infection.
Only five of the 48 patients in this study were admit-
ted with gastrointestinal diseases or disorders. One of
the five patients was diagnosed with CDI, and this
patient had a positive GeneXpert C. difficile test on an-
other occasion during the admission. The other 4 pa-
tients had a GI malignancy (2 patients), Crohn’s disease
(1 patient) or ulcer of the oesophagus (1 patient).
There were 16 patients who tested positive for C. difficile
by GeneXpert on stool tests taken at different times. Eight
of these 16 patients had another positive sample tested dur-
ing the same episode of disease. Five of these patients had
at least one previous positive test for C. difficile before this
episode. The remaining patients (3) were tested positive at
a later time.
When we examined the mortality rate among these 48
patients, 10 of them died in the hospital, with 4 deaths
due to respiratory illnesses, 2 due to CNS disease, 2
infections, 1 cancer, and 1 cardiac disease. The clinical
outcome of these patients did not seem to be associated
with CDI.
Discussion
Choice of optimal tests is based on various factors, includ-
ing sensitivity, specificity, cost and turnaround time. Real
time PCR (GeneXpert) has been used at this facility as the
primary CDI test, and while agreement between GeneXpert
and culture was high, toxigenic C. difficile was recovered
from 50 samples that tested negative by GeneXpert assay
(2.2 % of the total samples that were tested by GeneXpert
C. difficile epi test over the study period).
In this study, we used a two-step test (culture followed
by PCR) to isolate and identify C. difficile from stool
samples. This method is labor intensive and requires
days to produce results, thus it is not suitable for use in
clinical laboratory. However, toxin PCR and ribotyping
data obtained are very useful to track and study CDI
cases. Laboratory tests used to diagnose CDI were
discussed in the introduction, and many molecular
methods use the tcdB as a target for detecting toxigenic
C. difficile directly from stool sample. One of the newer
methods for analysing C. difficile is by using MALDI-
TOF, which is able to identify and differentiate between
different riboytpes [21, 22], however to use this method,
C. difficile must be recovered by culture, which would
not be feasible for a diagnostic laboratory.
The false negative results obtained in the subset of
GeneXpert C. difficile samples might have been due to low
levels of C. difficile that have fallen below the level of detec-
tion by PCR. This observation (toxigenic C. difficile present
at or below the limit of detection of the Xpert® C.difficile
assay) has been reported previously in a study evaluating
the use of GeneXpert for detection of environmental
contamination with C. difficile, where only one-third of en-
vironmental specimens positive by toxigenic C. difficile
culture were detectable as positive by the GeneXpert
assay [23]. Another study examined the indeterminate
results for tcdB GeneXpert C. difficile PCR assay,
which are defined as the detection of a typical PCR
amplification curve for tcdB gene with an Ept >10
that was interpreted as negative by the GeneXpert®
assay [24]. This study found that at least one third of
these results are associated with positive C. difficile
culture [24].
A recent study has shown an association between C.
difficile fecal load and the results of routinely used diag-
nostic tests [25]. The authors concluded that the associ-
ation between bacterial load and the results of ToxAB
and CCTA is likely indirect, as these latter assays detect
the presence of toxins rather than the bacteria per se
[25]. Unfortunately, this study examined only PCR
Table 3 The breakdown of results of other GeneXpert tests
(if patients have been tested more than once)
Number of
patients




16 Patients tested only once 16 0
16 Patients Tested Negative on
other occasions
16 0
8 Patients Tested Positive on
other occasions
4 4
8 Patients Tested both Positive and
Negative on other occasions
3 5
GeneXpert negative/ Culture positive (50 samples from 48 patients or 2.2 % of
total testing volume)
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positive samples, which would exclude any false negative
samples that might have been missed by PCR [25].
Other studies that compared the GeneXpert C. difficile
epi test to culture methods has shown a sensitivity, spe-
cificity, PPV and NPV of 98.8, 90.8, 56.6, and 99.8 %
respectively, while the values were 93.5, 94.0, 73.0, and
98.8 % when enriched TC was used [5]. Our data shows
a higher number of false negative samples compared to
this study. As mentioned before, a false negative C. diffi-
cile test might be related to the limit of detection of the
assay. An additional explanation of the results was pro-
vided by another study that was performed to examine
patients who tested positive for C. difficile after repeated
PCR. This study found that patients who test positive for
C. difficile by PCR within 7 days of a negative test are
more likely to have a history of CDI than are patients
who test negative with repeat PCR [26]. This scenario
has been seen in at least 5 cases in our study. Due to the
high sensitivity and nature of the PCR assays in general,
which can detect DNA material even in the absence of
viable bacterial cells or spores, it is more likely to en-
counter false positive PCR results for C. difficile when
compared to culture method.
Due to the high sensitivity of molecular testing for C.
difficile, repeated testing or testing as a proof of cure is
usually not recommended. During the time of this study,
repeated samples were not rejected by the diagnostic
lab, and these samples were tested by both GeneXpert
and culture methods. This provided valuable informa-
tion on how the test performed on these repeated sam-
ples. Close to 32 % of samples described in this study
came from patients that were tested only once during
the study period for C. difficile. The rest of the samples
were tested multiple times, sometimes with mixed
results (summarized in Table 3). In several instances, we
have seen patients that have produced both positive to
negative results several times. C. difficile isolated from
these patients have consistently produced the same ribo-
type. There is a possibility that these patients were re-
infected with C. difficile of the same ribotype, but given
the genetic diversity of the isolates we encountered at
HSN, this possibility was not strong. Rather, the stronger
possibility indicates that these patients consistently
carried the same C. difficile strain, even when C. difficile
could not be isolated from stool. Treatments given to
CDI patients have been also shown to affect the C. diffi-
cile test results [27].
The other significant aspect of this study is that all
patients tested with false negative results had diarrhea or
liquid stools. Misdiagnosing symptomatic patients who
have diarrhea may result in missing the chance to initi-
ate treatment earlier and isolating these patients, thus
increasing the chances of transmitting the bacterium to
other patients.
Conclusion
In conclusion, although molecular methods are con-
sidered among the most sensitive methods available
for clinical diagnosis of CDI, it seems inevitable that
some cases which are positive for C. difficile might be
missed when using this method, or any other method
for that matter. Even though in most of the cases that
were reviewed in this work, the presence of C. diffi-
cile did not seem to contribute to the clinical picture
or the illness of the affected patients (either the C.
difficile was not producing significant symptoms, or
the clinical picture of these patients didn’t seem
affected by the presence of C. difficile), it would be
reasonable to suggest that clinicians always keep in
mind that any diagnostic method, no matter how
sensitive, can miss sometimes. Being aware of the pa-
tient’s symptoms, and considering a repeat test for C.
difficile, if CDI is still suspected as a cause of illness
might help in identifying patients with CDI.
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